Related Experiment Video
Updated: Jan 22, 2026
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
Establishment of the PDTX model of gynecological tumors
Wen Yang1, Wen-Sheng Fan1, Ming-Xia Ye1
1Department of Obstetrics and Gynecology, Chinese PLA General Hospital 28 Fuxing Road, Haidian District, Beijing 100853, China.
Objective:
Fresh tumor tissues from patients with gynecological tumors were obtained by surgery or biopsy, and transplanted into NOD-Prkdcem26ll2rgem26Nju (NCG) mice to establish a patient-derived tumor xenograft (PDTX).
Materials And Methods:
A total of 15 patients with gynecologic tumors were enrolled into the present study. Among these patients, 12 patients had epithelial fallopian tube/ovarian/peritoneal cancer, one patient had metastatic ovarian cancer, and two patients had cervical cancer. Furthermore, among these patients, three patients were treated with puncture or microscopy biopsy, six patients underwent laparoscopic surgery, and six patients underwent robotic surgery. The tumor formation latency, tumor formation rate, tumor volume, tumor invasion and metastasis of the transplanted tumor were observed, the consistency of the PDTX model tumor tissue and patient's primary tumor tissue was compared by pathological H&E staining, and pharmacodynamics testing was performed.
Results:
Seven of 15 PDTX models were successfully established, with a success rate of 46.7%. The tumor formation time ranged within 21-130 days, with a median tumor formation time of 73 days. The PDTX model maintained the differentiation, morphological and structural characteristics of tumor cells, and the pharmacodynamic test was completed in five patients.
Conclusion:
The PDTX model is highly consistent with the pathology of the patient's tumor, and can be used as a substitute for clinical patients to guide the accurate treatment and scientific research of gynecological tumors.
Insights
Patient-derived tumor xenograft (PDTX) models were established from gynecological tumors in NCG mice. These models accurately reflect patient tumor pathology, aiding in personalized treatment and research.
Area of Science:
- Oncology
- Translational Medicine
- Animal Models
Background:
- Gynecological tumors present a significant health challenge.
- Effective preclinical models are crucial for advancing treatment strategies.
- Patient-derived tumor xenografts (PDTX) offer a promising avenue for personalized medicine.
Purpose of the Study:
- To establish and validate a PDTX model for gynecological tumors.
- To assess the fidelity of the PDTX model compared to original patient tumors.
- To evaluate the utility of the PDTX model for guiding gynecological cancer treatment and research.
Main Methods:
- Fresh tumor tissues from 15 gynecological cancer patients were xenografted into NOD-Prkdcem26ll2rgem26Nju (NCG) mice.
- Tumor formation rate, latency, volume, invasion, and metastasis were monitored.
- Pathological H&E staining and pharmacodynamic testing were performed to assess model consistency and utility.
Main Results:
- A 46.7% success rate was achieved in establishing 7 out of 15 PDTX models.
- Tumor formation occurred between 21-130 days (median 73 days).
- The established PDTX models retained the differentiation, morphology, and structural characteristics of the original tumors, with successful pharmacodynamic testing in five cases.
Conclusions:
- The developed PDTX model demonstrates high consistency with patient tumor pathology.
- PDTX models serve as a valuable substitute for clinical patients in gynecological oncology research.
- These models can guide accurate treatment decisions and facilitate scientific advancements in gynecological tumors.
More Related Videos
08:42Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
07:26Author Spotlight: Creating Human Vascularized Micro-Tumors as Models for Translational Cancer Research
Published on: September 15, 2023
Related Concept Videos
01:27Tumor Immunotherapy
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:17The Tumor Microenvironment
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...